Examkin

Question

Difficulty: HardDepressive Disorders

A 45-year-old man presents to the clinic with a 6-week history of persistently depressed mood, profound anhedonia, terminal insomnia, 5-kg (11-lb) weight loss, and difficulty concentrating. He denies any suicidal ideation and exhibits no psychotic features. He has no prior psychiatric or medical history and is currently treatment-naive. Based on standard clinical guidelines, arrange the following management steps in the most appropriate chronological sequence for this patient. Assume that at each subsequent step, the patient experiences an inadequate clinical response despite adequate trial duration, documented medication adherence, and good tolerability.

  1. 1Screen for a history of elevated mood, impulsivity, and decreased need for sleep.
  2. 2Initiate monotherapy with a first-line antidepressant, such as a selective serotonin reuptake inhibitor (SSRI).
  3. 3Increase the dose of the initial antidepressant to the maximum tolerated therapeutic level.
  4. 4Augment the regimen with an evidence-based adjunctive agent or switch to a different antidepressant class.
  5. 5Refer the patient for neuromodulation therapy, such as electroconvulsive therapy (ECT).

Answer

The correct clinical sequence is: 1) Screen for bipolar disorder, 2) Initiate an SSRI, 3) Optimize the SSRI dose, 4) Augment or switch antidepressants, and 5) Refer for ECT.
The standard stepped-care algorithm for major depressive disorder (MDD) begins with accurate diagnosis, which strictly requires ruling out bipolar disorder to prevent antidepressant-induced mania. Once confirmed as unipolar depression, a first-line agent (e.g., SSRI, SNRI, bupropion, mirtazapine) is initiated. If the initial dose yields a partial or non-response after an adequate duration (typically 4-6 weeks) with good tolerability, optimizing the dose of the current agent is preferred. If maximizing the dose fails, the next step involves switching to a different antidepressant class or augmenting with a second-line agent (e.g., aripiprazole, lithium). Finally, electroconvulsive therapy (ECT) or other neuromodulation therapies are indicated for true treatment-resistant depression, defined as the failure of at least two adequate trials of different pharmacotherapies in the absence of psychiatric emergencies (where ECT might be moved to first-line).

Step-by-Step Solution

1
Assess diagnostic criteria and definitively rule out bipolar disorder.
The patient is screened for past manic or hypomanic episodes.
Unopposed antidepressants can precipitate mania in patients with underlying but undiagnosed bipolar disorder.
2
Initiate first-line pharmacotherapy.
An SSRI or other first-line antidepressant is prescribed.
This is the standard initial evidence-based treatment for moderate-to-severe unipolar major depressive disorder.
3
Manage the initial inadequate response.
The dose of the initial SSRI is increased to the maximum tolerated dose.
Patients often require dose titration to achieve clinical remission; a trial should not be abandoned prematurely if the drug is well tolerated.
4
Manage the failure of an optimized initial monotherapy.
An augmenting agent (e.g., a second-generation antipsychotic) is added, or the drug class is switched.
Failure of an optimized first-line agent requires a change in pharmacologic strategy to achieve remission.
5
Manage true treatment-resistant depression (TRD).
The patient is referred for electroconvulsive therapy (ECT).
ECT is indicated for depression that has failed multiple adequate pharmacologic trials in a non-emergent setting, establishing a diagnosis of TRD.

Key Concept

Stepped-care treatment algorithm for Major Depressive Disorder (MDD) and Treatment-Resistant Depression
Rate this question

Topics

Depressive Disorders

More questions from this topic